

Table 1.15

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Both Sexes, 18 SEER Areas, 2011-2013

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	39.04	( 38.96, 39.13 )	39.20	( 39.10, 39.29 )	36.65	( 36.40, 36.90 )
Invasive and In Situ	41.39	( 41.31, 41.48 )	41.55	( 41.46, 41.65 )	37.98	( 37.73, 38.24 )
Oral Cavity and Pharynx	1.12	( 1.11, 1.14 )	1.17	( 1.16, 1.19 )	0.80	( 0.77, 0.84 )
Esophagus	0.49	( 0.48, 0.50 )	0.52	( 0.51, 0.53 )	0.42	( 0.39, 0.45 )
Stomach	0.85	( 0.83, 0.86 )	0.75	( 0.73, 0.76 )	1.04	( 0.99, 1.08 )
Colon and Rectum	4.39	( 4.36, 4.42 )	4.28	( 4.25, 4.31 )	4.64	( 4.55, 4.73 )
Invasive and In Situ	4.54	( 4.51, 4.57 )	4.42	( 4.39, 4.46 )	4.83	( 4.74, 4.93 )
Liver and Intrahepatic Bile Duct	0.95	( 0.94, 0.96 )	0.86	( 0.84, 0.87 )	0.99	( 0.95, 1.03 )
Pancreas	1.54	( 1.52, 1.56 )	1.53	( 1.51, 1.55 )	1.60	( 1.54, 1.65 )
Larynx	0.34	( 0.33, 0.35 )	0.35	( 0.34, 0.35 )	0.42	( 0.40, 0.45 )
Invasive and In Situ	0.36	( 0.36, 0.37 )	0.37	( 0.36, 0.38 )	0.45	( 0.42, 0.47 )
Lung and Bronchus	6.46	( 6.42, 6.49 )	6.59	( 6.56, 6.63 )	6.18	( 6.08, 6.29 )
Melanoma of the Skin	2.13	( 2.11, 2.14 )	2.49	( 2.47, 2.51 )	0.10	( 0.09, 0.11 )
Invasive and In Situ	3.63	( 3.61, 3.66 )	4.15	( 4.12, 4.18 )	0.13	( 0.12, 0.15 )
Breast	6.41	( 6.38, 6.44 )	6.48	( 6.44, 6.51 )	6.09	( 5.99, 6.18 )
Invasive and In Situ	7.60	( 7.57, 7.64 )	7.64	( 7.60, 7.68 )	7.29	( 7.19, 7.40 )
Urinary Bladder (Invasive and In Situ)	2.38	( 2.36, 2.40 )	2.58	( 2.56, 2.61 )	1.28	( 1.23, 1.33 )
Kidney and Renal Pelvis	1.62	( 1.61, 1.64 )	1.67	( 1.65, 1.69 )	1.59	( 1.54, 1.64 )
Brain and Other Nervous System	0.62	( 0.61, 0.63 )	0.68	( 0.67, 0.69 )	0.35	( 0.33, 0.38 )
Thyroid	1.19	( 1.18, 1.20 )	1.25	( 1.23, 1.26 )	0.69	( 0.66, 0.72 )
Hodgkin Lymphoma	0.21	( 0.20, 0.22 )	0.22	( 0.22, 0.23 )	0.19	( 0.18, 0.21 )
Non-Hodgkin Lymphoma	2.10	( 2.08, 2.12 )	2.20	( 2.17, 2.22 )	1.29	( 1.24, 1.33 )
Myeloma	0.75	( 0.74, 0.77 )	0.69	( 0.68, 0.70 )	1.32	( 1.28, 1.37 )
Leukemia	1.49	( 1.48, 1.51 )	1.56	( 1.54, 1.58 )	1.05	( 1.00, 1.09 )
Acute Lymphocytic Leukemia	0.13	( 0.13, 0.14 )	0.14	( 0.14, 0.15 )	0.08	( 0.07, 0.09 )
Chronic Lymphocytic Leukemia	0.56	( 0.55, 0.57 )	0.60	( 0.59, 0.61 )	0.38	( 0.35, 0.41 )
Acute Myeloid Leukemia	0.48	( 0.47, 0.49 )	0.49	( 0.48, 0.50 )	0.36	( 0.34, 0.39 )
Chronic Myeloid Leukemia	0.19	( 0.18, 0.19 )	0.19	( 0.19, 0.20 )	0.14	( 0.13, 0.16 )
Kaposi Sarcoma	0.12	( 0.11, 0.12 )	0.13	( 0.13, 0.14 )	0.05	( 0.04, 0.06 )
Mesothelioma	0.04	( 0.04, 0.05 )	0.04	( 0.03, 0.04 )	0.08	( 0.07, 0.09 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.15 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Both Sexes, 18 SEER Areas, 2011-2013

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	34.09 ( 33.77, 34.43 )	33.08 ( 31.90, 34.37 )	35.60 ( 35.31, 35.89 )
Invasive and In Situ	35.47 ( 35.14, 35.81 )	34.16 ( 32.95, 35.45 )	36.84 ( 36.54, 37.14 )
Oral Cavity and Pharynx	0.90 ( 0.85, 0.95 )	1.02 ( 0.85, 1.32 )	0.77 ( 0.73, 0.81 )
Esophagus	0.28 ( 0.25, 0.32 )	0.35 ( 0.25, 0.61 )	0.36 ( 0.34, 0.40 )
Stomach	1.67 ( 1.59, 1.76 )	1.27 ( 1.04, 1.62 )	1.37 ( 1.31, 1.43 )
Colon and Rectum	4.66 ( 4.53, 4.79 )	5.02 ( 4.55, 5.60 )	4.26 ( 4.16, 4.37 )
Invasive and In Situ	4.80 ( 4.68, 4.94 )	5.08 ( 4.60, 5.66 )	4.38 ( 4.28, 4.49 )
Liver and Intrahepatic Bile Duct	1.83 ( 1.76, 1.91 )	1.40 ( 1.20, 1.72 )	1.63 ( 1.58, 1.70 )
Pancreas	1.66 ( 1.59, 1.75 )	1.33 ( 1.05, 1.73 )	1.60 ( 1.53, 1.67 )
Larynx	0.16 ( 0.14, 0.19 )	0.21 ( 0.14, 0.45 )	0.28 ( 0.25, 0.31 )
Invasive and In Situ	0.19 ( 0.16, 0.22 )	0.22 ( 0.15, 0.46 )	0.29 ( 0.27, 0.32 )
Lung and Bronchus	5.54 ( 5.40, 5.69 )	5.68 ( 5.19, 6.28 )	4.05 ( 3.95, 4.16 )
Melanoma of the Skin	0.17 ( 0.15, 0.20 )	0.46 ( 0.35, 0.72 )	0.54 ( 0.50, 0.58 )
Invasive and In Situ	0.23 ( 0.21, 0.27 )	0.79 ( 0.63, 1.08 )	0.85 ( 0.81, 0.91 )
Breast	5.68 ( 5.56, 5.80 )	4.79 ( 4.39, 5.29 )	5.21 ( 5.11, 5.31 )
Invasive and In Situ	6.99 ( 6.86, 7.11 )	5.68 ( 5.26, 6.21 )	6.12 ( 6.02, 6.23 )
Urinary Bladder (Invasive and In Situ)	1.45 ( 1.37, 1.53 )	1.19 ( 0.94, 1.56 )	1.60 ( 1.53, 1.67 )
Kidney and Renal Pelvis	1.07 ( 1.02, 1.13 )	2.14 ( 1.86, 2.53 )	1.78 ( 1.73, 1.85 )
Brain and Other Nervous System	0.40 ( 0.37, 0.44 )	0.37 ( 0.27, 0.62 )	0.52 ( 0.49, 0.55 )
Thyroid	1.27 ( 1.23, 1.32 )	0.90 ( 0.76, 1.17 )	1.10 ( 1.06, 1.14 )
Hodgkin Lymphoma	0.11 ( 0.10, 0.14 )	0.13 ( 0.07, 0.37 )	0.20 ( 0.18, 0.22 )
Non-Hodgkin Lymphoma	1.84 ( 1.76, 1.92 )	1.63 ( 1.36, 2.02 )	2.13 ( 2.06, 2.21 )
Myeloma	0.54 ( 0.50, 0.59 )	0.76 ( 0.58, 1.06 )	0.78 ( 0.74, 0.83 )
Leukemia	0.99 ( 0.94, 1.05 )	1.06 ( 0.88, 1.37 )	1.25 ( 1.20, 1.31 )
Acute Lymphocytic Leukemia	0.11 ( 0.09, 0.12 )	0.16 ( 0.11, 0.39 )	0.19 ( 0.18, 0.21 )
Chronic Lymphocytic Leukemia	0.17 ( 0.14, 0.20 )	0.25 ( 0.15, 0.51 )	0.31 ( 0.28, 0.34 )
Acute Myeloid Leukemia	0.48 ( 0.44, 0.52 )	0.32 ( 0.23, 0.57 )	0.46 ( 0.42, 0.49 )
Chronic Myeloid Leukemia	0.14 ( 0.12, 0.17 )	0.17 ( 0.11, 0.40 )	0.18 ( 0.16, 0.20 )
Kaposi Sarcoma	0.06 ( 0.05, 0.09 )	0.08 ( 0.03, 0.32 )	0.11 ( 0.09, 0.13 )
Mesothelioma	0.02 ( 0.01, 0.03 )	0.01 ( 0.00, 0.25 )	0.07 ( 0.06, 0.09 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Males, 18 SEER Areas, 2011-2013

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	40.84	( 40.71, 40.96 )	40.52	( 40.39, 40.66 )	39.33	( 38.95, 39.72 )
Invasive and In Situ	42.33	( 42.21, 42.46 )	42.05	( 41.91, 42.19 )	39.64	( 39.26, 40.04 )
Oral Cavity and Pharynx	1.59	( 1.56, 1.61 )	1.66	( 1.64, 1.69 )	1.17	( 1.10, 1.23 )
Esophagus	0.78	( 0.76, 0.80 )	0.83	( 0.81, 0.85 )	0.61	( 0.56, 0.66 )
Stomach	1.05	( 1.03, 1.07 )	0.95	( 0.93, 0.97 )	1.20	( 1.13, 1.28 )
Colon and Rectum	4.56	( 4.52, 4.61 )	4.43	( 4.39, 4.48 )	4.77	( 4.64, 4.91 )
Invasive and In Situ	4.73	( 4.69, 4.78 )	4.59	( 4.54, 4.64 )	5.00	( 4.86, 5.14 )
Liver and Intrahepatic Bile Duct	1.35	( 1.33, 1.37 )	1.21	( 1.19, 1.23 )	1.48	( 1.42, 1.55 )
Pancreas	1.57	( 1.54, 1.59 )	1.57	( 1.54, 1.60 )	1.49	( 1.42, 1.58 )
Larynx	0.57	( 0.56, 0.58 )	0.57	( 0.56, 0.59 )	0.73	( 0.68, 0.79 )
Invasive and In Situ	0.61	( 0.60, 0.63 )	0.61	( 0.60, 0.63 )	0.77	( 0.72, 0.82 )
Lung and Bronchus	7.00	( 6.95, 7.05 )	6.99	( 6.94, 7.05 )	7.28	( 7.11, 7.46 )
Melanoma of the Skin	2.67	( 2.64, 2.71 )	3.10	( 3.07, 3.14 )	0.09	( 0.07, 0.12 )
Invasive and In Situ	4.49	( 4.45, 4.54 )	5.10	( 5.05, 5.15 )	0.12	( 0.09, 0.15 )
Breast	0.12	( 0.12, 0.13 )	0.12	( 0.12, 0.13 )	0.16	( 0.14, 0.19 )
Invasive and In Situ	0.14	( 0.13, 0.14 )	0.14	( 0.13, 0.14 )	0.18	( 0.16, 0.22 )
Prostate	12.88	( 12.81, 12.94 )	12.10	( 12.02, 12.17 )	17.02	( 16.78, 17.27 )
Testis	0.39	( 0.38, 0.40 )	0.46	( 0.45, 0.47 )	0.10	( 0.09, 0.12 )
Urinary Bladder (Invasive and In Situ)	3.78	( 3.74, 3.82 )	4.10	( 4.05, 4.14 )	1.84	( 1.75, 1.94 )
Kidney and Renal Pelvis	2.06	( 2.04, 2.09 )	2.12	( 2.09, 2.15 )	1.95	( 1.87, 2.03 )
Brain and Other Nervous System	0.69	( 0.68, 0.71 )	0.76	( 0.74, 0.78 )	0.40	( 0.37, 0.44 )
Thyroid	0.62	( 0.60, 0.63 )	0.65	( 0.64, 0.67 )	0.29	( 0.26, 0.32 )
Hodgkin Lymphoma	0.23	( 0.22, 0.24 )	0.24	( 0.23, 0.25 )	0.21	( 0.19, 0.24 )
Non-Hodgkin Lymphoma	2.36	( 2.33, 2.39 )	2.46	( 2.43, 2.49 )	1.38	( 1.31, 1.45 )
Myeloma	0.88	( 0.86, 0.90 )	0.82	( 0.80, 0.84 )	1.38	( 1.31, 1.46 )
Leukemia	1.77	( 1.74, 1.80 )	1.85	( 1.82, 1.88 )	1.18	( 1.12, 1.26 )
Acute Lymphocytic Leukemia	0.14	( 0.14, 0.15 )	0.16	( 0.15, 0.16 )	0.08	( 0.07, 0.10 )
Chronic Lymphocytic Leukemia	0.70	( 0.68, 0.72 )	0.74	( 0.72, 0.76 )	0.47	( 0.43, 0.52 )
Acute Myeloid Leukemia	0.54	( 0.53, 0.56 )	0.56	( 0.54, 0.58 )	0.39	( 0.35, 0.43 )
Chronic Myeloid Leukemia	0.23	( 0.22, 0.24 )	0.24	( 0.23, 0.25 )	0.15	( 0.13, 0.18 )
Kaposi Sarcoma	0.19	( 0.18, 0.20 )	0.21	( 0.20, 0.22 )	0.08	( 0.06, 0.10 )
Mesothelioma	0.07	( 0.07, 0.08 )	0.06	( 0.06, 0.07 )	0.15	( 0.14, 0.18 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.16 - continued

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Males, 18 SEER Areas, 2011-2013

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	35.16 ( 34.66, 35.67 )	32.13 ( 30.40, 34.08 )	37.49 ( 37.03, 37.96 )
Invasive and In Situ	35.49 ( 34.99, 36.00 )	32.52 ( 30.77, 34.49 )	37.97 ( 37.51, 38.45 )
Oral Cavity and Pharynx	1.22 ( 1.13, 1.31 )	1.34 ( 1.05, 1.94 )	1.10 ( 1.03, 1.18 )
Esophagus	0.44 ( 0.39, 0.51 )	0.58 ( 0.37, 1.14 )	0.57 ( 0.52, 0.64 )
Stomach	1.97 ( 1.85, 2.10 )	1.48 ( 1.14, 2.13 )	1.57 ( 1.48, 1.69 )
Colon and Rectum	5.13 ( 4.94, 5.33 )	4.99 ( 4.33, 5.91 )	4.59 ( 4.43, 4.75 )
Invasive and In Situ	5.30 ( 5.11, 5.50 )	5.07 ( 4.41, 5.99 )	4.74 ( 4.58, 4.91 )
Liver and Intrahepatic Bile Duct	2.56 ( 2.44, 2.70 )	1.67 ( 1.39, 2.26 )	2.25 ( 2.15, 2.37 )
Pancreas	1.66 ( 1.56, 1.79 )	1.37 ( 0.96, 2.10 )	1.52 ( 1.42, 1.63 )
Larynx	0.29 ( 0.24, 0.34 )	0.34 ( 0.21, 0.87 )	0.51 ( 0.46, 0.58 )
Invasive and In Situ	0.33 ( 0.28, 0.40 )	0.37 ( 0.23, 0.89 )	0.55 ( 0.50, 0.62 )
Lung and Bronchus	6.79 ( 6.56, 7.03 )	6.30 ( 5.52, 7.34 )	4.67 ( 4.49, 4.86 )
Melanoma of the Skin	0.20 ( 0.17, 0.26 )	0.44 ( 0.30, 0.96 )	0.57 ( 0.51, 0.65 )
Invasive and In Situ	0.28 ( 0.24, 0.35 )	0.83 ( 0.59, 1.40 )	0.89 ( 0.81, 0.98 )
Breast	0.06 ( 0.04, 0.09 )	0.03 ( 0.01, 0.57 )	0.09 ( 0.06, 0.14 )
Invasive and In Situ	0.06 ( 0.05, 0.10 )	0.05 ( 0.01, 0.58 )	0.09 ( 0.07, 0.14 )
Prostate	8.63 ( 8.40, 8.87 )	6.65 ( 5.92, 7.64 )	11.95 ( 11.72, 12.20 )
Testis	0.15 ( 0.13, 0.18 )	0.35 ( 0.27, 0.84 )	0.35 ( 0.33, 0.39 )
Urinary Bladder (Invasive and In Situ)	2.36 ( 2.22, 2.52 )	1.89 ( 1.42, 2.68 )	2.56 ( 2.42, 2.72 )
Kidney and Renal Pelvis	1.44 ( 1.34, 1.54 )	2.61 ( 2.21, 3.29 )	2.19 ( 2.08, 2.31 )
Brain and Other Nervous System	0.44 ( 0.39, 0.50 )	0.48 ( 0.33, 1.01 )	0.57 ( 0.52, 0.63 )
Thyroid	0.67 ( 0.62, 0.73 )	0.34 ( 0.23, 0.84 )	0.49 ( 0.45, 0.54 )
Hodgkin Lymphoma	0.13 ( 0.11, 0.17 )	0.18 ( 0.08, 0.70 )	0.22 ( 0.19, 0.27 )
Non-Hodgkin Lymphoma	2.11 ( 1.99, 2.24 )	1.73 ( 1.29, 2.47 )	2.34 ( 2.23, 2.46 )
Myeloma	0.64 ( 0.58, 0.73 )	0.73 ( 0.48, 1.33 )	0.91 ( 0.84, 0.99 )
Leukemia	1.17 ( 1.08, 1.28 )	1.20 ( 0.91, 1.80 )	1.46 ( 1.36, 1.57 )
Acute Lymphocytic Leukemia	0.12 ( 0.10, 0.15 )	0.14 ( 0.08, 0.65 )	0.20 ( 0.18, 0.24 )
Chronic Lymphocytic Leukemia	0.22 ( 0.18, 0.28 )	0.26 ( 0.11, 0.81 )	0.37 ( 0.32, 0.45 )
Acute Myeloid Leukemia	0.55 ( 0.49, 0.62 )	0.38 ( 0.24, 0.91 )	0.51 ( 0.46, 0.59 )
Chronic Myeloid Leukemia	0.16 ( 0.14, 0.21 )	0.23 ( 0.12, 0.75 )	0.23 ( 0.19, 0.28 )
Kaposi Sarcoma	0.10 ( 0.07, 0.14 )	0.17 ( 0.07, 0.71 )	0.18 ( 0.15, 0.22 )
Mesothelioma	0.03 ( 0.02, 0.06 )	0.03 ( 0.00, 0.56 )	0.10 ( 0.08, 0.15 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry. A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17

Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity  
Females, 18 SEER Areas, 2011-2013

Site	All Races		Whites		Blacks	
	Percent	( 95% C.I. )	Percent	( 95% C.I. )	Percent	( 95% C.I. )
All Sites	37.54	( 37.43, 37.65 )	38.14	( 38.01, 38.27 )	34.36	( 34.03, 34.70 )
Invasive and In Situ	40.75	( 40.63, 40.86 )	41.35	( 41.22, 41.48 )	36.63	( 36.29, 36.97 )
Oral Cavity and Pharynx	0.68	( 0.66, 0.69 )	0.70	( 0.68, 0.71 )	0.48	( 0.44, 0.52 )
Esophagus	0.22	( 0.21, 0.23 )	0.22	( 0.21, 0.23 )	0.25	( 0.22, 0.28 )
Stomach	0.66	( 0.64, 0.67 )	0.56	( 0.54, 0.57 )	0.90	( 0.84, 0.96 )
Colon and Rectum	4.23	( 4.19, 4.27 )	4.14	( 4.10, 4.18 )	4.53	( 4.41, 4.66 )
Invasive and In Situ	4.36	( 4.32, 4.40 )	4.26	( 4.22, 4.31 )	4.70	( 4.57, 4.83 )
Liver and Intrahepatic Bile Duct	0.57	( 0.55, 0.58 )	0.51	( 0.49, 0.52 )	0.55	( 0.51, 0.59 )
Pancreas	1.52	( 1.49, 1.54 )	1.49	( 1.46, 1.51 )	1.69	( 1.61, 1.77 )
Larynx	0.12	( 0.12, 0.13 )	0.13	( 0.12, 0.14 )	0.16	( 0.14, 0.18 )
Invasive and In Situ	0.13	( 0.13, 0.14 )	0.14	( 0.13, 0.15 )	0.17	( 0.15, 0.19 )
Lung and Bronchus	6.00	( 5.95, 6.04 )	6.26	( 6.21, 6.32 )	5.27	( 5.14, 5.41 )
Melanoma of the Skin	1.64	( 1.62, 1.66 )	1.94	( 1.91, 1.97 )	0.11	( 0.09, 0.13 )
Invasive and In Situ	2.87	( 2.84, 2.90 )	3.31	( 3.27, 3.34 )	0.15	( 0.12, 0.17 )
Breast	12.43	( 12.36, 12.49 )	12.70	( 12.63, 12.77 )	11.38	( 11.20, 11.56 )
Invasive and In Situ	14.77	( 14.70, 14.84 )	15.02	( 14.94, 15.09 )	13.67	( 13.47, 13.86 )
Cervix Uteri	0.62	( 0.61, 0.63 )	0.60	( 0.59, 0.62 )	0.75	( 0.71, 0.80 )
Corpus and Uterus, NOS	2.80	( 2.77, 2.83 )	2.86	( 2.83, 2.90 )	2.62	( 2.54, 2.71 )
Invasive and In Situ	2.82	( 2.79, 2.85 )	2.89	( 2.85, 2.92 )	2.65	( 2.56, 2.74 )
Ovary <sup>a</sup>	1.28	( 1.26, 1.30 )	1.34	( 1.32, 1.36 )	0.97	( 0.92, 1.03 )
Urinary Bladder (Invasive and In Situ)	1.13	( 1.11, 1.15 )	1.20	( 1.18, 1.22 )	0.81	( 0.76, 0.87 )
Kidney and Renal Pelvis	1.21	( 1.19, 1.23 )	1.24	( 1.22, 1.26 )	1.27	( 1.21, 1.34 )
Brain and Other Nervous System	0.54	( 0.53, 0.56 )	0.60	( 0.58, 0.62 )	0.31	( 0.29, 0.35 )
Thyroid	1.76	( 1.74, 1.78 )	1.86	( 1.83, 1.88 )	1.06	( 1.02, 1.12 )
Hodgkin Lymphoma	0.19	( 0.18, 0.20 )	0.20	( 0.20, 0.21 )	0.17	( 0.16, 0.20 )
Non-Hodgkin Lymphoma	1.87	( 1.84, 1.89 )	1.95	( 1.93, 1.98 )	1.21	( 1.15, 1.27 )
Myeloma	0.65	( 0.63, 0.66 )	0.57	( 0.55, 0.58 )	1.28	( 1.22, 1.35 )
Leukemia	1.24	( 1.22, 1.26 )	1.30	( 1.28, 1.32 )	0.93	( 0.88, 0.99 )
Acute Lymphocytic Leukemia	0.12	( 0.12, 0.13 )	0.13	( 0.13, 0.14 )	0.07	( 0.06, 0.09 )
Chronic Lymphocytic Leukemia	0.44	( 0.43, 0.45 )	0.47	( 0.45, 0.48 )	0.30	( 0.27, 0.34 )
Acute Myeloid Leukemia	0.42	( 0.41, 0.44 )	0.44	( 0.42, 0.45 )	0.35	( 0.31, 0.38 )
Chronic Myeloid Leukemia	0.15	( 0.14, 0.16 )	0.16	( 0.15, 0.16 )	0.13	( 0.11, 0.16 )
Kaposi Sarcoma	0.05	( 0.05, 0.06 )	0.06	( 0.05, 0.06 )	0.03	( 0.02, 0.04 )
Mesothelioma	0.01	( 0.01, 0.01 )	0.01	( 0.01, 0.01 )	0.01	( 0.01, 0.02 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.

Table 1.17 - continued

## Lifetime Risk (Percent) of Being Diagnosed with Cancer by Site and Race/Ethnicity

Females, 18 SEER Areas, 2011-2013

Site	Asian/Pacific Islanders	American Indian/ Alaska Natives <sup>a</sup>	Hispanics <sup>b</sup>
	Percent ( 95% C.I. )	Percent ( 95% C.I. )	Percent ( 95% C.I. )
All Sites	33.35 ( 32.92, 33.79 )	34.20 ( 32.55, 36.02 )	34.40 ( 34.02, 34.79 )
Invasive and In Situ	35.65 ( 35.21, 36.10 )	35.95 ( 34.28, 37.80 )	36.37 ( 35.98, 36.77 )
Oral Cavity and Pharynx	0.63 ( 0.57, 0.70 )	0.73 ( 0.53, 1.20 )	0.48 ( 0.43, 0.53 )
Esophagus	0.14 ( 0.11, 0.19 )	0.15 ( 0.07, 0.58 )	0.18 ( 0.15, 0.22 )
Stomach	1.43 ( 1.32, 1.54 )	1.07 ( 0.79, 1.61 )	1.20 ( 1.13, 1.29 )
Colon and Rectum	4.25 ( 4.09, 4.43 )	5.04 ( 4.38, 5.91 )	3.97 ( 3.83, 4.12 )
Invasive and In Situ	4.38 ( 4.21, 4.57 )	5.08 ( 4.41, 5.95 )	4.07 ( 3.93, 4.22 )
Liver and Intrahepatic Bile Duct	1.20 ( 1.12, 1.30 )	1.12 ( 0.85, 1.65 )	1.08 ( 1.01, 1.16 )
Pancreas	1.66 ( 1.56, 1.78 )	1.30 ( 0.94, 1.92 )	1.68 ( 1.58, 1.78 )
Larynx	0.05 ( 0.04, 0.09 )	0.08 ( 0.03, 0.52 )	0.07 ( 0.05, 0.09 )
Invasive and In Situ	0.06 ( 0.04, 0.10 )	0.08 ( 0.03, 0.52 )	0.07 ( 0.05, 0.10 )
Lung and Bronchus	4.53 ( 4.36, 4.71 )	5.15 ( 4.53, 5.98 )	3.58 ( 3.45, 3.73 )
Melanoma of the Skin	0.15 ( 0.12, 0.18 )	0.49 ( 0.33, 0.93 )	0.52 ( 0.48, 0.58 )
Invasive and In Situ	0.19 ( 0.16, 0.23 )	0.76 ( 0.54, 1.24 )	0.84 ( 0.78, 0.92 )
Breast	10.50 ( 10.30, 10.72 )	9.38 ( 8.62, 10.34 )	9.95 ( 9.77, 10.14 )
Invasive and In Situ	12.94 ( 12.72, 13.18 )	11.14 ( 10.32, 12.15 )	11.73 ( 11.54, 11.93 )
Cervix Uteri	0.62 ( 0.57, 0.68 )	0.79 ( 0.61, 1.25 )	0.88 ( 0.83, 0.94 )
Corpus and Uterus, NOS	2.30 ( 2.21, 2.40 )	2.25 ( 1.92, 2.81 )	2.50 ( 2.41, 2.59 )
Invasive and In Situ	2.31 ( 2.22, 2.41 )	2.26 ( 1.93, 2.82 )	2.51 ( 2.43, 2.61 )
Ovary <sup>c</sup>	1.10 ( 1.03, 1.18 )	1.33 ( 1.03, 1.87 )	1.22 ( 1.15, 1.29 )
Urinary Bladder (Invasive and In Situ)	0.70 ( 0.63, 0.79 )	0.56 ( 0.38, 1.03 )	0.81 ( 0.74, 0.88 )
Kidney and Renal Pelvis	0.77 ( 0.70, 0.84 )	1.69 ( 1.32, 2.29 )	1.44 ( 1.37, 1.52 )
Brain and Other Nervous System	0.37 ( 0.33, 0.43 )	0.26 ( 0.16, 0.69 )	0.47 ( 0.43, 0.52 )
Thyroid	1.81 ( 1.74, 1.90 )	1.45 ( 1.19, 1.95 )	1.71 ( 1.65, 1.78 )
Hodgkin Lymphoma	0.10 ( 0.08, 0.13 )	0.09 ( 0.03, 0.53 )	0.18 ( 0.16, 0.21 )
Non-Hodgkin Lymphoma	1.61 ( 1.51, 1.72 )	1.56 ( 1.23, 2.13 )	1.95 ( 1.86, 2.06 )
Myeloma	0.46 ( 0.41, 0.52 )	0.79 ( 0.56, 1.29 )	0.68 ( 0.62, 0.74 )
Leukemia	0.84 ( 0.77, 0.92 )	0.94 ( 0.71, 1.44 )	1.09 ( 1.02, 1.17 )
Acute Lymphocytic Leukemia	0.10 ( 0.08, 0.13 )	0.18 ( 0.10, 0.60 )	0.18 ( 0.16, 0.20 )
Chronic Lymphocytic Leukemia	0.12 ( 0.09, 0.15 )	0.24 ( 0.11, 0.70 )	0.26 ( 0.22, 0.31 )
Acute Myeloid Leukemia	0.42 ( 0.38, 0.48 )	0.27 ( 0.17, 0.70 )	0.41 ( 0.37, 0.46 )
Chronic Myeloid Leukemia	0.12 ( 0.09, 0.16 )	0.11 ( 0.06, 0.53 )	0.14 ( 0.11, 0.17 )
Kaposi Sarcoma	0.03 ( 0.02, 0.07 )	0.00 ( 0.00, 0.45 )	0.05 ( 0.04, 0.08 )
Mesothelioma	0.01 ( 0.00, 0.03 )	0.00 ( 0.00, 0.45 )	0.05 ( 0.03, 0.08 )

Devcan Version 6.7.4, August 2016, National Cancer Institute (<http://surveillance.cancer.gov/devcan/>).

Source: SEER 18 areas (San Francisco, Connecticut, Detroit, Hawaii, Iowa, New Mexico, Seattle, Utah, Atlanta, San Jose-Monterey, Los Angeles, Alaska Native Registry, Rural Georgia, California excluding SF/SJM/LA, Kentucky, Louisiana, New Jersey, and Georgia excluding ATL/RG).

Note: Invasive cancer only unless specified otherwise.

<sup>a</sup> Underlying incidence data for American Indian/Alaska Native are based on the CHSDA (Contract Health Service Delivery Area) counties.

<sup>b</sup> Hispanic is not mutually exclusive from whites, blacks, Asian Pacific Islanders, and American Indians/Alaska Natives. Underlying incidence data for Hispanics are based on NHIA and exclude cases from the Alaska Native Registry.

<sup>c</sup> Ovary excludes borderline cases or histologies 8442, 8451, 8462, 8472, and 8473.

A percent or confidence interval value of 0.00 represents a value that is below 0.005.